# AllRock Bio

> AllRock Bio is a privately held, clinical-stage biotechnology company developing ROC-101, a once-daily oral inhibitor of both ROCK1 and ROCK2, for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Founded in 2024 by former CinCor executives Catherine Pearce and Justin Thompson, the Natick company licensed its lead asset from Sanofi, raised a $50 million Series A, and began dosing a 40-person Phase 2a study in 2026.

- **Founded:** 2024
- **Headquarters:** Natick, United States
- **Founders:** Catherine J. Pearce (CEO and Founder), Justin Thompson (CBO and Founder)
- **Team size:** 11-50 employees publicly listed on LinkedIn; supplied company data reports 21 employees.
- **Products:** ROC-101, ROCSTAR Phase 2a study
- **Notable:** Licensed ROC-101 exclusively from Sanofi and launched publicly with a $50 million Series A in September 2025., Completed a randomized, double-blind Phase 1 program in healthy volunteers with favorable reported safety, target engagement and no associated hypotension., Presented Phase 1 data at the 2025 European Respiratory Society Congress.

## Products & services

- **ROC-101** — An investigational, once-daily oral small molecule that inhibits ROCK1 and ROCK2; it is being evaluated with standard care in PAH and ILD-PH. It is not approved for commercial use.
- **ROCSTAR Phase 2a study** — A recruiting, open-label, single-arm, multicenter study of approximately 40 adults receiving ROC-101 plus standard care for 24 weeks, with pulmonary vascular resistance and safety as primary outcomes.

## Achievements

- Licensed ROC-101 exclusively from Sanofi and launched publicly with a $50 million Series A in September 2025.
- Completed a randomized, double-blind Phase 1 program in healthy volunteers with favorable reported safety, target engagement and no associated hypotension.
- Presented Phase 1 data at the 2025 European Respiratory Society Congress.
- Published peer-reviewed preclinical ROC-101 results in Pharmacological Research in January 2026.
- Dosed the first participants in the Phase 2a ROCSTAR trial by April 2026.
- Expanded ROCSTAR to 19 listed clinical locations across eight countries as of May 2026.

## Latest updates

- **2026-05** — The ROCSTAR ClinicalTrials.gov record was updated to recruiting, with 19 locations listed across the United States, Australia, Canada and Europe.
- **2026-04** — AllRock announced that the first patients had been dosed in the Phase 2a ROCSTAR study.
- **2026-01** — Peer-reviewed preclinical research reported favorable lung distribution and reduced fibrosis, inflammation and vascular remodeling in animal models.
- **2025-09** — AllRock presented Phase 1 data at ERS Congress and announced a $50 million Series A co-led by Versant Ventures and Westlake BioPartners.

## Links

- Website: https://allrockbio.com
- LinkedIn: https://www.linkedin.com/company/allrock-bio

---

Profile page: https://yespress.io/allrock-bio
Published by YesPress — https://yespress.io
Last updated: 2026-08-20